Blinklab Limited · ASX:BB1
Blinklab — Bioshares Biotech Summit 2024
21 slides from Blinklab's conference presentation, Jul 12, 2024
Slide 1: Bioshares Biotech Summit 2024 presentation
blinkltab ASX:BBI CEO, Henk-Jan Boele will be presenting at: BI@SHARES Biotech Summit 2024 Saturday, 13 July 2024 10:15 AM - 10:35 AM Esplanade Hotel in Fremantle, Western Australia . HENK-JAN BOELE ‘CEO & Co-founder be M M
Slide 2: Early and accurate diagnosis of autism and ADHD
For personal use only Early and accurate diagnosis of autism and ADHD Introducing a breakthrough AI-powered ASX:BB1, BlinkLabsmartphone platform Ltd, Sydney 126 Phillip for Street Level 5, NSWneurological testing 2000, Dr. Henk-Jan Boele CEO ASX:BB1, BlinkLab Ltd, Sydney 126 Phillip Street Level 5,
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 4: Autism is a $700B market in 2024 in the US alone
Autism is a $700B market in 2024 in the US alone ”The economic burden is significant and alarming” 1 For personal use only • Autism prevalence has grown to 2-4% among children2 • Autism healthcare expenses are soaring3 Costs for an autism diagnostic evaluation: $1,000 to $5,000. Costs of care are ar
Slide 5: Autism diagnosis is expensive, inaccurate, and often late
Autism diagnosis is expensive, inaccurate, and often late For personal use only Parental Autism Autism Diagnosis at Late observations screening diagnostic evaluation age 5-6 intervention Concerns arise By primary care Formal diagnosis requires input from Family Yielding poor about child’s physician,
Slide 6: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis For personal use only Parental BlinkLab Diagnostic Diagnosis at Early and personalized intervention observations screening evaluation age 2-3 and accurate monitoring Concerns arise Using our Using biomarkers. Initial diagnosis Intervention st
Slide 7: For personal use only
For personal use only
Slide 8: Our patented technology: neuroscience on a smartphone
Our patented technology: neuroscience on a smartphone Minuscule facial reflexes, evoked by our app, For personal use only generate a digital biomarker for autism. Evokes facial reflexes By presenting visual and auditory stimuli during smartphone use. Computer vision Facial features are tracked on th
Slide 9: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 10: BlinkLab is fully developed and ready to use
BlinkLab is fully developed and ready to use Validated in >8,000 subjects tested globally, including people with limited access to healthcare. For personal use only ● Remote testing Enables accessible and global diagnostics. ● Scalable solution Easily adaptable for clinical and diverse research need
Slide 11: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions For personal use only Autism/ ADHD Functional Neurological Disorders Prof. Samuel S. -H. Wang Alzheimer’s/FTD (Princeton University) “The BlinkLab app is easy to operate, substantially reduces the costs of diagnosis, and produces reliable and
Slide 12: Breakthrough data from large scale study on diagnostic accuracy
Breakthrough data from large scale study on diagnostic accuracy of BlinkLab For personal use only Scores based on BlinkLab testing only. No additional questionnaires, such as ADOS of M-CHAT. Paper submitted for publication
Slide 13: BlinkLab outperforms FDA-approved digital peers
BlinkLab outperforms FDA-approved digital peers We are leaders in the rapidly growing space of digital diagnostics and therapeutics. For personal use only Sensitivity 85% 52% 71% Specificity 84% 19% 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k)
Slide 14: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models.
Slide 15: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 16: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 17: R&D Pipeline
R&D Pipeline Our pipeline of diagnostic products, relevant development state and regulatory pathway. For personal use only Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory approval Post authorization Diagnostic: BlinkLab Dx FDA 510(
Slide 18: Important milestones
Important milestones News pipeline: Updates on regulatory studies on autism and ADHD and new partnerships For personal use only Milestone Timeframe Start of activities for FDA registrational study in autism (appointment of CRO, lead clinical investigator, etc.) *1H 2024 Initiation of ADHD discovery
Slide 19: Capital structure
Capital structure For personal use only (ASX.BB1) Public Market Overview (10 July 2024) Share Price A$0.27 Shares on issue 99,150,003 Founders' shareholding percentage 37% Founders’ options on issue @ 25c 33,750,000 Chairman options @ 25c 2,000,000 Performance rights 3,000,000 Fully diluted share ca
Slide 20: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p
Slide 21: For further information please contact
ASX:BB1 For personal use only For further information please contact: Henk-Jan Boele Brian Leedman Chief Executive Officer Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M +61 (0) 412 281 780 BlinkLab Ltd, Sydney 126 Phillip Street Level 5, NSW 2000, Dr. Henk-J